companydata.dkcompanydata.dk

Ascendis Pharma Growth Disorders A/S: Financial statements 2024

CVR: 32323677

Source: annual report 2024, Danish Business Authority

01/01/2024 – 31/12/2024

Ascendis Pharma Growth Disorders A/S (CVR 32323677) has filed annual accounts for 2024. In 2024, the company reported a gross profit of EUR -157,522,000 and a net result of EUR -176,019,000 compared with EUR -120,223,434 the year before. Equity in the 2024 report amounted to EUR -498,015,000.

Gross Profit
EUR -157,522,000
Profit/Loss
EUR -176,019,000
Equity
EUR -498,015,000
Total Assets
EUR 8,933,000
Employees
0

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2024--157.5M EUR-176M EUR-498M EUR0
2023--114.2M EUR-120.2M EUR-322M EUR0
2022--57M EUR-61.4M EUR-201.8M EUR0
2021--47.9M EUR-51M EUR-140.4M EUR0
2020--30.2M EUR-32.1M EUR-89.5M EUR0

Official annual report

View the official annual report directly on the page with a Pro subscription.

Screen every Danish company

Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.

Try company screening

Events in 2024

Ascendis Pharma Growth Disorders A/S: The 2023 annual report is outApr 3, 2024

Ascendis Pharma Growth Disorders A/S has published its annual report for 2023. Gross profit came to DKK -114,185,673, and the net result was DKK -120,223,434.

About Ascendis Pharma Growth Disorders A/S

Ascendis Pharma Growth Disorders A/S is a Danish company of the type Aktieselskab based in Hellerup, founded in 2012. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named ASCENDIS PHARMA, CIRCULATORY DISEASES DIVISION A/S and ASCENDIS PHARMA RELAXIN DIVISION A/S. The management consists of Jan Møller Mikkelsen. The board consists of Michael Wolff Jensen (chair), Anni Lotte Kirstine Pedersen and Jan Møller Mikkelsen. The company is owned by ASCENDIS PHARMA A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of EUR -190,726,000 and a net result of EUR -225,725,000 compared with EUR -176,019,000 the year before. Equity in the 2025 report amounted to EUR -723,740,000.

Source: annual report 2025, Danish Business Authority